In an adult with type 1 or type 2 diabetes for > 5 years and poor glycemic control, how should I screen for autonomic neuropathy and manage orthostatic hypotension, gastroparesis, bladder dysfunction, and erectile dysfunction?

Screening and Management of Autonomic Neuropathy in Diabetes

Screening Protocol

Begin annual cardiovascular autonomic neuropathy screening at diagnosis for type 2 diabetes and after 5 years for type 1 diabetes, using heart rate variability testing with deep breathing, orthostatic vital signs, and a systematic symptom review. 1, 2

Cardiovascular Autonomic Testing

• Measure heart rate variability with deep breathing as the primary cardiovagal function test; this detects early autonomic dysfunction even when patients are asymptomatic 1, 2
• Check orthostatic vital signs by measuring blood pressure after 5 minutes lying/sitting, then at 1 and 3 minutes after standing; a systolic drop ≥20 mmHg or diastolic drop ≥10 mmHg without appropriate heart rate increase is positive 1, 2, 3
• Document resting heart rate; tachycardia >100 bpm indicates advanced autonomic disease 1, 2

Systematic Symptom Assessment

• Screen for hypoglycemia unawareness (loss of adrenergic warning symptoms) 1, 2
• Elicit gastrointestinal symptoms: gastroparesis (early satiety, nausea, vomiting, erratic glucose control), constipation, diarrhea, fecal incontinence 1, 2
• Ask about genitourinary dysfunction: erectile dysfunction, retrograde ejaculation, urinary urgency, frequency, nocturia, weak stream, incontinence 1, 2
• Assess sudomotor function: abnormal sweating patterns (increased or decreased), dry cracked skin 1, 2

Critical pitfall: Up to 50% of autonomic neuropathy cases are asymptomatic, so screening must not be omitted based on absence of complaints 2

---

Management of Orthostatic Hypotension

Implement comprehensive non-pharmacological measures first, then add midodrine 2.5–10 mg three times daily if symptoms persist, while monitoring for supine hypertension at every visit. 3

Non-Pharmacological Interventions (First-Line)

• Discontinue or switch (not just reduce) medications that worsen orthostatic hypotension: alpha-1 blockers, diuretics, vasodilators, centrally-acting antihypertensives 3
• Increase fluid intake to 2–3 liters daily unless heart failure is present 3
• Increase salt consumption to 6–9 grams daily if not contraindicated 3
• Elevate head of bed by 10 degrees during sleep to prevent nocturnal polyuria 3
• Teach physical counter-maneuvers: leg crossing, squatting, stooping, muscle tensing during symptomatic episodes 3
• Use waist-high compression stockings and abdominal binders to reduce venous pooling 3
• Recommend smaller, more frequent meals to reduce postprandial hypotension 3
• Acute water ingestion ≥480 mL provides temporary relief with peak effect at 30 minutes 3

Pharmacological Management (Second-Line)

• Midodrine 2.5–5 mg three times daily, titrate up to 10 mg three times daily as the preferred first-line agent with FDA approval 3
• Fludrocortisone 0.05–0.1 mg daily, titrate to 0.1–0.3 mg daily, can be used as monotherapy or combined with midodrine 3

Concurrent Hypertension Management

• Use long-acting dihydropyridine calcium channel blockers or RAS inhibitors as first-line antihypertensives 3
• Avoid beta-blockers unless compelling indications exist 3

Critical monitoring: Supine hypertension is the most important limiting factor and can cause end-organ damage; measure supine blood pressure at every follow-up visit 3

---

Management of Gastroparesis

Exclude mechanical obstruction with esophagogastroduodenoscopy before confirming delayed gastric emptying with 4-hour gastric emptying scintigraphy, then treat with dietary modifications and metoclopramide. 1, 2, 4

Diagnostic Approach

• Suspect gastroparesis in patients with erratic glucose control or upper GI symptoms (nausea, vomiting, early satiety, bloating) without other identified cause 1, 5
• Perform upper endoscopy to exclude gastric outlet obstruction or peptic ulcer disease before specialized testing 1, 2
• Confirm diagnosis with 4-hour gastric emptying scintigraphy using digestible solids at 15-minute intervals (gold standard) 2, 4

Treatment Strategy

• Dietary modifications: small, frequent meals that are low in fat and low in fiber (contrary to typical constipation advice, as high fiber worsens dysmotility) 4
• Prefer liquid nutritional supplements because gastric motility is better preserved for liquids than solids 4
• Metoclopramide as the primary prokinetic agent to enhance gastric emptying 4, 6
• Anti-emetics for symptom control 2

Critical pitfall: Gastroparesis causes "gastric hypoglycemia" by delaying gastric emptying, leading to unexplained hypoglycemia in insulin-treated patients; adjust insulin timing and dosing accordingly 2

---

Management of Bladder Dysfunction

Implement timed voiding schedules first, then use cholinergic agents or intermittent catheterization for severe neurogenic bladder. 3

Evaluation Triggers

• Evaluate bladder dysfunction in patients with recurrent urinary tract infections, pyelonephritis, incontinence, or palpable bladder 5
• Refer to urology for specialized assessment including anorectal manometry when indicated 5

Treatment Approach

• Timed voiding schedules as first-line management 3
• Cholinergic agents for moderate dysfunction 3
• Intermittent catheterization for severe cases 3

---

Management of Erectile Dysfunction

Treat with phosphodiesterase-5 inhibitors (sildenafil, tadalafil) after completing a comprehensive workup to exclude other causes. 3, 6

Comprehensive Evaluation

• Medical and sexual history 5
• Psychological evaluation 5
• Hormone levels 5
• Nocturnal penile tumescence testing 5
• Cardiovascular autonomic function tests 5
• Penile and brachial blood pressure measurements 5

Treatment

• Sildenafil or tadalafil as first-line pharmacotherapy 3, 6

---

Management of Constipation

Initiate a low-fiber diet with frequent small meals, use metoclopramide as the primary prokinetic, and treat small intestinal bacterial overgrowth with rifaximin when present. 4

Dietary Modifications

• Low-fiber diet (contrary to typical constipation management, as high fiber worsens dysmotility in autonomic neuropathy) 4
• Frequent small meals that are low in fat 4
• Liquid nutritional supplements preferred over solids 4
• Increase fluid and salt intake 4

Pharmacological Management

• Metoclopramide as the primary prokinetic agent 4
• Rifaximin as first-line antibiotic for small intestinal bacterial overgrowth (SIBO), which is virtually inevitable in chronic dysmotility 4
• Rotate antibiotic courses every 2–6 weeks with 1–2 week drug-free intervals if SIBO persists 4

Medications to Avoid

• Never use opioids, loperamide, or diphenoxylate as they worsen intestinal dysmotility 4
• Avoid tricyclic antidepressants as they aggravate constipation, urinary retention, and orthostatic hypotension 4

---

Disease-Modifying Management

Achieve intensive glycemic control in type 1 diabetes (Level A evidence) and multifactorial cardiovascular risk reduction in type 2 diabetes (Level B evidence) to prevent and slow autonomic neuropathy progression. 1, 2, 3

Glycemic Control

• Intensive insulin therapy in type 1 diabetes prevents and delays onset of autonomic neuropathy 2, 3
• Optimizing glucose control in type 2 diabetes slows (but does not reverse) neuropathy progression 2, 3

Cardiovascular Risk Reduction

• Control hypertension to target blood pressure goals 2, 3
• Manage dyslipidemia according to contemporary guidelines 2, 3
• Multifactorial risk reduction is especially critical in type 2 diabetes, where autonomic neuropathy risk is influenced by factors beyond glycemia 1, 2

Important distinction: Only intensive glycemic control in type 1 diabetes modifies disease course; symptomatic treatments improve quality of life but do not alter progression 2

---

Prognostic Implications

Cardiovascular autonomic neuropathy independently doubles mortality risk and predicts silent myocardial ischemia, making early detection and intensive risk factor management essential. 1, 2, 5

• Reduced heart rate variability roughly doubles the relative risk of death, with risk escalating as autonomic neuropathy advances 2, 5
• Silent myocardial ischemia risk is doubled in patients with cardiovascular autonomic neuropathy 2, 5
• Prevalence of confirmed autonomic neuropathy is approximately 20% in unselected diabetic populations, reaching 65% with increasing age and diabetes duration 1